Skip to main content
SpringerLink
Log in

GlaxoSmithKline's ofatumumab is likely to become the new gold standard treatment for relapsed/refractory chronic lymphocytic leukaemia

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources Inc.GlaxoSmithKline's Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL. Media Release: 20 Jan 2009. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

GlaxoSmithKline's ofatumumab is likely to become the new gold standard treatment for relapsed/refractory chronic lymphocytic leukaemia. Pharmacoecon. Outcomes News 570, 11 (2009). https://doi.org/10.2165/00151234-200905700-00035

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905700-00035

Keywords

Search

Navigation